Kari Grønås
Directeur/Bestuurslid bij SPAGO NANOMEDICAL AB
Vermogen: 4 185 $ op 30-04-2024
Actieve functies van Kari Grønås
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| SPAGO NANOMEDICAL AB | Directeur/Bestuurslid | 01-01-2018 | - |
| Independent Dir/Board Member | 01-01-2018 | - | |
| ULTIMOVACS ASA | Directeur/Bestuurslid | 01-01-2019 | - |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Directeur/Bestuurslid | 21-05-2012 | - |
| Algemeen Directeur | 21-05-2012 | - | |
| Norwegian Cancer Society | Directeur/Bestuurslid | - | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Directeur/Bestuurslid | - | - |
Loopbaan van Kari Grønås
Eerdere bekende functies van Kari Grønås
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BERGENBIO ASA | Directeur/Bestuurslid | 01-02-2016 | 13-03-2019 |
| Independent Dir/Board Member | 01-02-2016 | 13-03-2019 | |
| ONCOPEPTIDES AB | Directeur/Bestuurslid | - | - |
| SOFTOX SOLUTIONS | Directeur/Bestuurslid | - | - |
| Norwegian Pharmaceutical Society | Voorzitter | - | - |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Opleiding van Kari Grønås
| University of Oslo | Graduate Degree |
Statistieken
Internationaal
| Noorwegen | 11 |
| Zweden | 3 |
Operationeel
| Director/Board Member | 9 |
| Independent Dir/Board Member | 2 |
| Chief Operating Officer | 1 |
Sectoraal
| Health Technology | 8 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| BERGENBIO ASA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| Bedrijven in privébezit | 5 |
|---|---|
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Beurs
- Insiders
- Kari Grønås
- Ervaring
